Immune responses of infants vaccinated with serotype 6B pneumococcal polysaccharide conjugated with tetanus toxoid
| Autor: | Sveinn Kjartansson, Ingileif Jonsdottir, Thorolfur Gudnason, Sigurveig T. Sigurdardottir, Rachel Schneerson, Gerald Schiffman, Karl G. Kristinsson, Gestur Vidarsson, Steinn Jonsson, Helgi Valdimarsson |
|---|---|
| Přispěvatelé: | Academic Medical Center, Landsteiner Laboratory |
| Rok vydání: | 1997 |
| Předmět: |
Microbiology (medical)
Serotype Male chemical and pharmacologic phenomena medicine.disease_cause complex mixtures Microbiology Phagocytosis Nasopharynx Streptococcus pneumoniae Tetanus Toxoid Medicine Humans Saliva Vaccines Conjugate business.industry Tetanus Immunogenicity Polysaccharides Bacterial Vaccination Toxoid Infant medicine.disease Antibodies Bacterial respiratory tract diseases Infectious Diseases Otitis Pediatrics Perinatology and Child Health Immunology Immunoglobulin A Secretory Female medicine.symptom business Meningitis |
| Zdroj: | Pediatric infectious disease journal, 16(7), 667-674. Lippincott Williams and Wilkins |
| ISSN: | 0891-3668 |
| Popis: | Streptococcus pneumoniae is a major cause of meningitis, bacteremia, pneumonia and otitis media. Pneumococcal polysaccharides are not immunogenic in infants, but improved immunogenicity of polysaccharide-protein conjugates has been demonstrated. Antibiotic-resistant pneumococci have increased the need for an effective vaccine. To study the safety and immunogenicity of a pneumococcal type 6B polysaccharidetetanus toxoid conjugate (Pn6B-TT) in infants and to assess the function of antibodies. Healthy infants were injected, Group A at 3, 4 and 6 months (n = 21) and Group B at 7 and 9 months (n = 19). Booster injection was given at 18 months. Antibodies were measured by enzyme-linked immunosorbent assay and radioimmunoassay, and functional activity was measured by opsonization of radiolabeled pneumococci. Nasopharyngeal cultures were obtained. No significant adverse reactions were observed. Pn6B-IgG (enzyme-linked immunosorbent assay) increased to a geometric mean of 0.62 microgram/ml (P = 0.367, compared with prevaccination titers) in Group A at 7 months and 1.22 micrograms/ml (P 300 ng of antibody N/ml. Opsonic activity, after initial and booster vaccinations, correlated with Pn6B-antibody titers. Three infants with nasopharyngeal cultures repeatedly positive for serogroup 6 had poor serum IgG responses. Our results demonstrate that Pn6B-TT is safe, elicits functional antibodies and memory responses in infants |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|